On May 31st local time, Sanofi and Regenerative announced that the European Medicines Agency's Committee on Medicines for Human Use (CHMP) has adopted a positive opinion recommending the approval of Dupixent (Duprizumab) in the treatment of adult patients with chronic obstructive pulmonary disease (COPD) in the European Union. Two Phase 3 trials have shown that Dupixent can significantly reduce acute exacerbation of COPD and improve lung function. It is expected that the European Commission will announce its final decision on the Dupixent application in the coming months.